BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
23.36
+0.32 (1.39%)
Nov 21, 2024, 2:44 PM EST - Market open
BridgeBio Pharma Employees
As of December 31, 2023, BridgeBio Pharma had 556 total employees, including 550 full-time and 6 part-time employees. The number of employees increased by 160 or 40.40% compared to the previous year.
Employees
556
Change (1Y)
160
Growth (1Y)
40.40%
Revenue / Employee
$391,664
Profits / Employee
-$789,317
Market Cap
4.41B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
ICU Medical | 14,000 |
Integer Holdings | 10,500 |
Haemonetics | 3,657 |
Oscar Health | 2,400 |
Alkermes | 2,100 |
Ultragenyx Pharmaceutical | 1,276 |
Prestige Consumer Healthcare | 570 |
Axsome Therapeutics | 545 |
BBIO News
- 2 days ago - BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market - Benzinga
- 3 days ago - Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months - GlobeNewsWire
- 3 days ago - BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director - Business Wire
- 3 days ago - BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia - GlobeNewsWire
- 7 days ago - BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats - Seeking Alpha
- 16 days ago - BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio Management - GlobeNewsWire
- 22 days ago - BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors - Business Wire
- 4 weeks ago - BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 - GlobeNewsWire